Pet Pharm Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	159.02	130.7	117.87	75.74
Revenue Growth (YoY)	109.96%	10.89%	55.62%	-
Cost of Revenue	76.12	60.74	53.27	39.88
Gross Profit	82.91	69.96	64.59	35.86
Selling, General & Admin	61.33	49.74	44.16	31.71
Research & Development	11.85	12.14	14.05	7.79
Operating Expenses	73.23	61.85	57.01	40.7
Operating Income	9.67	8.11	7.59	-4.84
Interest Expense	-0.22	-0.18	-0.18	-0.2
Interest & Investment Income	5.62	4.1	1.67	0.45
Other Non Operating Income (Expenses)	0.35	0.38	0.07	0.77
Pretax Income	17.16	12.42	9.15	-3.81
Income Tax Expense	-2.09	-2.09	-	-
Net Income	19.25	14.51	9.15	-3.81
Net Income to Common	19.25	14.51	9.15	-3.81
Net Income Growth	-	58.54%	-	-
Shares Outstanding (Basic)	46	41	30	24
Shares Outstanding (Diluted)	46	41	30	24
Shares Change (YoY)	92.45%	36.54%	23.95%	-
EPS (Basic)	0.42	0.36	0.31	-0.16
EPS (Diluted)	0.41	0.36	0.31	-0.16
EPS Growth	-	16.12%	-	-
Free Cash Flow	-114.46	-159.51	-22.02	-27.87
Free Cash Flow Per Share	-2.46	-3.91	-0.74	-1.16
Dividend Per Share	0.088	0.088	-	-
Gross Margin	52.13%	53.53%	54.80%	47.34%
Operating Margin	6.08%	6.21%	6.44%	-6.39%
Profit Margin	12.11%	11.10%	7.76%	-5.03%
Free Cash Flow Margin	-71.98%	-122.05%	-18.68%	-36.80%
EBITDA	31.73	27.72	24.34	9.46
EBITDA Margin	19.95%	21.21%	20.65%	12.49%
D&A For EBITDA	22.06	19.6	16.75	14.3
EBIT	9.67	8.11	7.59	-4.84
EBIT Margin	6.08%	6.21%	6.44%	-6.39%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.